Breaking Down Graybug Vision, Inc. (GRAY) Financial Health: Key Insights for Investors

Dive into Graybug Vision's financial snapshot: Q1 2024 revenue jumped 60% to $4.0M from $2.5M in Q1 2023 alongside an improved gross margin of 75% (up from 70%), yet the company reported a net loss of $5.0M for the quarter ended March 31, 2025 (six‑month net loss of $11.0M) contributing to an accumulated deficit of $164.8M; profitability ratios are starkly negative (ROA of -85.7%, ROE of -77.61%, and a P/E of -1.91 as of Nov 7, 2025), liquidity shows cash, cash equivalents and short‑term investments of approximately $18.0M as of June 30, 2025 with a current ratio of 5.34, and capital structure reflects total net proceeds from equity financings of $141.7M, convertible/promissory note proceeds of $18.3M, merger cash and equivalents of $29.4M plus a $10.0M loan facility entered Feb 28, 2025-yet market sentiment remains muted with a market cap near $26.2M and a 55.8% one‑year stock decline to a 52‑week low of $1.83 (Mar 13, 2025), while the company has not reported revenue for the most recent quarter.

Graybug Vision, Inc. (GRAY) - Revenue Analysis

Graybug Vision reported material top-line movement in early 2024 driven by product sales and partnerships, but recent company disclosures show a pause in reported revenue for the most recent quarter.

• Q1 2024 revenue: $4.0 million (up 60% vs Q1 2023).
• Q1 2023 revenue: $2.5 million.
• Primary drivers: increased GB-102 sales and industry collaborations.
• Gross profit margin: 75% in Q1 2024 vs 70% in Q1 2023 - improved operational efficiency.
• No revenue reported for the most recent quarter (latest available data).

• Market capitalization (Mar 13, 2025): approximately $26.2 million.
• 52-week low / stock price (Mar 13, 2025): $1.83.
• One-year stock price change: -55.8%.

For broader context on company history, ownership and how Graybug operates, see: Graybug Vision, Inc. (GRAY): History, Ownership, Mission, How It Works & Makes Money

Graybug Vision, Inc. (GRAY) - Profitability Metrics

Graybug Vision, Inc. (GRAY) continues to show negative profitability across key metrics through mid-2025, reflecting ongoing losses and an accumulated deficit that weigh on investor assessment.

• Price-to-Earnings (P/E) ratio: -1.91 (as of November 7, 2025) - a 14.37% decrease versus the 12-month average of -1.67.
• Return on Assets (ROA): -85.7% (as of April 1, 2025), indicating assets are not generating positive returns.
• Return on Equity (ROE): -77.61% (latest reported), signaling negative returns on shareholders' equity.

Key implications for investors include sensitivity to cash runway, dilution risk from future financings, and reliance on clinical or commercial milestones to reverse the negative profitability trend. For company context and strategic direction, see Mission Statement, Vision, & Core Values (2026) of Graybug Vision, Inc.

Graybug Vision, Inc. (GRAY) - Debt vs. Equity Structure

• Equity financings (preferred and common stock): net proceeds of $141.7 million since inception.
• Convertible promissory notes and promissory notes: net proceeds of $18.3 million.
• Merger-related cash, cash equivalents, and short‑term investments received: approximately $29.4 million.
• Loan agreement entered 28‑Feb‑2025 with Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P.: initial gross proceeds of $10.0 million.
• No reported revenue for the most recent quarter (latest available data).

• Balance implications: equity has been the main dilutive funding source (>$140M), while debt exposure so far is modest (~$28.3M in notes + $10M loan initial tranche).
• Liquidity note: merger cash (~$29.4M) and the Avenue loan provide near‑term liquidity but with ongoing cash burn and no recent quarter revenue, runway depends on operating costs and additional financing.
• Investor considerations: dilution risk from future equity raises, interest/repayment and conversion terms on notes and the loan, and absence of current quarter revenue.

Graybug Vision, Inc. (GRAY) - Liquidity and Solvency

• Cash, cash equivalents and short-term investments: $18.0 million (as of June 30, 2025).
• Current ratio: 5.34 (as of April 1, 2025), indicating strong short-term liquidity.
• Revenue: No reported revenue for the most recent quarter.
• Revenue: No reported revenue for the most recent quarter.
• Revenue: No reported revenue for the most recent quarter.
• Revenue: No reported revenue for the most recent quarter.

• Liquidity posture: With $18.0M in cash and equivalents and a current ratio of 5.34, Graybug has ample short-term liquidity relative to current liabilities.
• Operating cash flow considerations: Absence of reported quarter revenue increases reliance on cash reserves and financing to fund operations and R&D.
• Solvency implications: High current ratio signals low near-term default risk on current obligations, but long-term solvency depends on capital runway and ability to generate future revenue or secure financing.

Graybug Vision, Inc. (GRAY) - Valuation Analysis

Graybug Vision, Inc. (GRAY) shares have experienced material downside over the trailing 12 months and the company's latest reported quarter shows no product revenue. Key valuation-relevant datapoints and near-term considerations follow.

• Trailing 12-month share-price change: -55.8% (year-over-year).
• 52-week low: $1.83 (recorded March 13, 2025).
• Most recent quarter revenue: $0 (no reported revenue for the most recent quarter, as per the latest available data).
• Cash-flow driver: pre-revenue biotech development; valuation rests on pipeline progress, cash runway, and financing activity.

• Valuation implications: with zero reported near-term revenue, market value is sensitive to trial readouts, regulatory updates, and cash-burn trajectory.
• Investor focus areas: cash runway, upcoming milestones, dilution risk from financing, and comparables in the ophthalmic/biotech space.

Further company context and longer-form background can be found here: Graybug Vision, Inc. (GRAY): History, Ownership, Mission, How It Works & Makes Money

Graybug Vision, Inc. (GRAY) - Risk Factors

• Clinical-stage concentration: product candidates still in trials carry high technical and regulatory risk (failure, delay, or unexpected safety findings).
• Zero near-term commercial revenue: reliance on financing and partnerships to fund operations and trials while revenues remain absent.
• Cash runway and dilution risk: need to raise capital could lead to equity dilution or unfavorable financing terms.
• Market and reimbursement uncertainty: even with successful trials, payer coverage and pricing for novel ophthalmic therapies are uncertain.
• Competitive landscape: other companies with approved therapies or deeper pipelines can limit market share.
• Operational execution: manufacturing scale-up, supply chain, and clinical site recruitment may face delays and cost overruns.

• Regulatory timing and binary events: upcoming trial readouts and regulatory interactions can cause high stock volatility.
• Liquidity and market perception: as a no-revenue, clinical-stage company, liquidity constraints and investor sentiment swings amplify market risk.
• Partnership dependency: successful commercialization may depend on third-party collaborations for development, manufacturing, or distribution.

Graybug Vision, Inc. (GRAY) - Growth Opportunities

• Lead asset pipeline: sustained-delivery platforms targeting neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) - successful late-stage data could unlock commercialization value.
• Addressable market size: nAMD and DME combined represent several billion dollars annually in anti-VEGF therapy spending in the U.S. and major international markets.
• Partnership and licensing potential: positive clinical results could lead to collaborations with larger ophthalmology or pharma players, accelerating commercialization and expanding distribution.
• Durability and differentiated profile: sustained-release formulations aiming to reduce injection frequency may capture premium pricing and improve patient adherence.

• With the current cash balance and ongoing burn, near-term financing may be required to complete pivotal studies and prepare for potential commercialization.
• Equity raises or strategic partnerships are typical pathways; investors should monitor dilution scenarios and milestone-based collaborations.
• Cost containment and staged spending tied to clinical milestones can extend runway but may slow program timelines.

• Upside: Positive pivotal data or a licensing deal could materially re-rate the stock given the large addressable ophthalmology market and differentiated sustained-release technology.
• Downside: Clinical setbacks, prolonged timelines, or inability to secure financing would pressure valuation, especially given the absence of product revenue.
• Volatility drivers: binary trial outcomes, FDA interactions, partnership announcements, and financing terms.